每经AI快讯，1月12日，合富中国(603122.SH)公告称，公司2025年1—12月合并营业收入为6.89亿元，较 上年同期下降26.67%。 （文章来源：每日经济新闻） ...

Core Viewpoint - The company reported a consolidated revenue of 689 million yuan for the period from January to December 2025, representing a decline of 26.67% compared to the same period last year [1] Group 1 - The company's consolidated revenue for 2025 is 689 million yuan [1] - The revenue decline of 26.67% indicates a significant downturn compared to the previous year [1]

Core Viewpoint - The company, HeFu China, reported a significant decline in consolidated revenue for the year 2025, indicating potential challenges in its financial performance [1] Financial Performance - The consolidated revenue for HeFu China in the period from January to December 2025 is projected to be 689 million yuan, which represents a decrease of 26.67% compared to the same period last year [1]

公司于2026年1月5日收到合富香港出具的《关于提前终止减持计划暨减持结果的告知函》，合富香 港自2025年12月24日至2025年12月31日期间内，通过集中竞价方式减持公司股份3,980,000股，占公司总 股本的0.9999%，以上减持已达到合富香港资金需求，合富香港决定提前终止本次减持计划，以表达对 公司未来发展的信心及支持。 合富中国的公告显示，2025年12月24日至2025年12月31日，合富香港通过集中竞价减持3,980,000 股，减持总金额99,193,707元。 中国经济网北京1月6日讯 合富中国(603122.SH)昨晚发布控股股东提前终止减持计划暨减持股份结 果公告。 本次减持计划实施前，合富中国控股股东合富（香港）控股有限公司（简称"合富香港"）持有公司 股票218,937,885股，占公司总股本的55.0022%，上述股份全部来源于公司IPO前取得，均为无限售流通 股。 公司于2025年12月3日披露了《合富（中国）医疗科技股份有限公司控股股东减持股份计划公告》 （公告编号：2025-065），合富香港计划通过大宗交易方式和集中竞价交易方式减持公司股份数量合计 不超过7,961, ...

Core Viewpoint - The company, Heff China (603122), is focusing its business on the Greater China market, primarily serving medical institutions in mainland China and Taiwan, positioning itself as a "partner for high-quality hospital development" [1] Business Focus - The company's current business focus is on the Greater China market, specifically targeting medical institutions in mainland China and Taiwan [1] - The company does not currently engage in business activities within EU countries [1] Strategic Direction - The management team is closely monitoring industry trends and actively seeking new project collaborations and investment opportunities to expand its business coverage [1] - The goal is to achieve long-term sustainable growth and create long-term investment value for investors [1]

Group 1 - Maduro denies all charges from the U.S. and claims he is still the President of Venezuela [2] - The U.S. has accused Maduro of drug terrorism conspiracy, cocaine smuggling conspiracy, and possession of firearms [2] - Maduro states he was forcibly taken from his home in Caracas [2] Group 2 - China condemns the U.S. for violating Venezuela's sovereignty and international principles [3] - The U.S. is accused of undermining multilateralism and threatening peace in Latin America and the Caribbean [3] Group 3 - Venezuela's oil exports have nearly dropped to zero due to U.S. sanctions and blockade [4] - The Venezuelan oil company is reducing production and closing some oil fields due to accumulated inventory [4] - Shortages of diluents for blending heavy crude oil are further restricting production activities [4] Group 4 - Trump claims the U.S. must have complete access to Venezuela's resources and asserts U.S. control over the country [5][6] - The U.S. Vice President's residence was attacked, with one suspect arrested [6] Group 5 - High expectations for Chinese stocks with projected annual growth of 15% to 20% in 2026 and 2027 [8] - Corporate earnings in China are expected to grow by 14% and 12% in 2026 and 2027, respectively [8] - Factors driving growth include AI applications, international expansion, and policies to reduce internal competition [8]

Group 1 - Victory Energy announced that its stock price increased by 213.97% from December 12 to December 29, 2025, leading to a review of trading fluctuations, with stock resuming trading on January 6, 2026 [2] - Tianqi Materials plans to conduct maintenance on its 150,000-ton liquid lithium hexafluorophosphate production line for 20 to 30 days, ensuring no significant impact on operations [3] - Yingfang Micro is planning to acquire controlling stakes in several companies, leading to a significant asset restructuring, with stock suspension starting January 6, 2026 [4] Group 2 - Weigao Blood Purification intends to acquire 100% of Weigao Purui for 8.511 billion yuan, which will enhance its product offerings in medical packaging [6] - Zhongtian Rocket reported losses in its carbon/carbon thermal field materials business due to intensified competition in the photovoltaic industry, significantly impacting its consolidated financial statements [7] - Fulin Precision plans to invest 6 billion yuan in a project to produce 500,000 tons of high-end lithium iron phosphate for energy storage, alongside additional projects for precursor materials [8] Group 3 - Deyun Co. announced that its actual controller was arrested for illegal public deposit collection, but this will not significantly affect the company's governance or operations [9] - Jushen Co. signed a 1.34 billion USD bauxite transfer agreement, which is expected to positively impact future financial performance [10] - Sanxia New Materials intends to acquire a 40% stake in a subsidiary for 0 yuan, which is classified as a related party transaction [11] Group 4 - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan for employee stock ownership plans, with a maximum price of 35 yuan per share [13] - Juxing Technology expects a net profit increase of 5.00% to 20.00% for 2025, projecting a profit of 2.419 billion to 2.764 billion yuan [15] - China National Materials Technology anticipates a net profit increase of 73.79% to 118.64% for 2025, driven by improved product structure and sales growth [16] Group 5 - Chifeng Gold forecasts a net profit increase of 70% to 81% for 2025, with gold product sales prices rising approximately 49% [17] - Dingtai High-Tech expects a net profit of 410 million to 460 million yuan for 2025, reflecting an 81% to 103% increase due to rising demand in high-end PCB markets [18] - Zhonggang Luoyang announced plans for shareholders to reduce their stakes by up to 1% of total shares [20]

（文章来源：证券日报） 证券日报网讯 1月5日，合富中国在互动平台回答投资者提问时表示，公司已多次发布有关股票交易异 常波动、严重异动波动及风险提示的公告，具体内容详见相关公告。公司会审慎判断，并严格遵循监管 机构关于股票交易严重异常波动的认定标准及程序。 ...

北京商报讯（记者 丁宁）1月5日晚间，合富中国（603122）发布公告称，公司于1月5日收到公司控股 股东合富（香港）控股有限公司（以下简称"合富香港"）出具的《关于提前终止减持计划暨减持结果的 告知函》，合富香港自2025年12月24日至2025年12月31日期间内，通过集中竞价方式减持公司股份398 万股，占公司总股本的0.9999%，以上减持已达到合富香港资金需求，合富香港决定提前终止本次减持 计划，以表达对公司未来发展的信心及支持。 据了解，合富中国于2025年12月3日披露称，合富香港计划通过大宗交易方式和集中竞价交易方式减持 公司股份数量合计不超过796.11万股（合计不超过公司总股本的2%）。 ...

Group 1 - Postal Savings Bank announced a cash dividend distribution of 14.772 billion yuan for the first half of 2025, with a dividend of 1.23 yuan per 10 shares [1] - Xinke Mobile plans to reduce its shareholding by up to 1%, amounting to a maximum of 34.1875 million shares, due to funding needs [1] - Defu Technology signed a cooperation letter with a leading domestic CCL company to supply high-end electronic circuit copper foil products, which is expected to positively impact the company's performance in 2026 [1] Group 2 - Sanxia New Materials intends to acquire 40% equity of Lingang New Materials for a transaction amount of 0 yuan, which constitutes a related party transaction [2] - Fulim Precision plans to invest a total of 87 billion yuan in projects for the production of high-end lithium iron phosphate for energy storage, with the main project estimated at 60 billion yuan [3] - Heng Rui Pharmaceutical received approval for clinical trials of HRS9531 injection in combination with HRS-5817 injection for treating obesity in adults [3] Group 3 - Quartz Co. was fined 2.7 million yuan for commercial secret infringement, with the company being the victim in this case [5] - ST Renfu received approval for clinical trials of HW221043 tablets for late-stage solid tumors, with no similar drugs approved domestically or internationally [6] - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical robotics and smart manufacturing [6] Group 4 - Xusheng Group received a notification from a North American electric vehicle manufacturer for a project with an estimated total sales amount of approximately 7.8 billion yuan over its lifecycle [6] - Deyun Co. announced that its actual controller was arrested for illegal public deposit collection, but this does not significantly impact the company's operations [7] - Shengyang Technology's subsidiary is advancing a project with a global satellite operator in South America, focusing on software licensing and product delivery [7] Group 5 - Hefei China announced a 1% reduction in shares by its controlling shareholder, who terminated the reduction plan early to express confidence in the company's future [8] - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui for 8.511 billion yuan, which will expand its business into drug delivery systems [10]